Drugs / ANTI-PSGL-1 ANTIBODY SELK2
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04540042 | Aug 2020 → Dec 2021 | asthma, chronic obstructive pulmonary disease | Tetherex Pharmaceuticals Corporation | Completed | No outcome recorded |
| Phase 2 | NCT03812328 | Feb → Oct 2019 | venous thromboembolism | Tetherex Pharmaceuticals Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANTI-PSGL-1 ANTIBODY SELK2 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594606 ↗ |
| Known as | SelK2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03812328 ↗ |
| Route | Intravenous | “I.V., single-dose” NCT03812328 ↗ |